


<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 371 CONCERNING A FILING UNDER 35 U.S.C.</b>		ATTORNEY'S DOCKET NUMBER TIP0045-USPCT
INTERNATIONAL APPLICATION NO. PCT/EP2004/050621	INTERNATIONAL FILING DATE 27 April 2004	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/554712</b>
PRIORITY DATE CLAIMED 28 April 2003		
TITLE OF INVENTION <b>HIV INTEGRASE INHIBITORS</b>		
APPLICANT(S) FOR DO/EO/US : VERSCHUEREN, Wim Gaston; DIERYNCK, Inge; SURLERAUX, Dominique, Louis, Nestor, Ghislain; DAEYAERT, Frederik, Frans, Desire		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below</p> <p>4. <input type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>    a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau), as well as the Published Application No. WO 2004/096807 A2</p> <p>    b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p>    c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>    a. <input type="checkbox"/> is attached hereto</p> <p>    b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>    a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>    b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>    c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>    d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) has been filed in the PCT Request (Rule 4.17 (iv)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
<b>Items 11 to 20 below concern document(s) or information included:</b>		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Copy of PCT Request with Declaration; Certificate Under 37 CFR 3.73 (b); Power of Attorney; PCT Notification of the Recording of a Change; Gene Sequence Listing (paper); Sequence Listing (Diskette); Verified Statement Under 37 CFR §1.821(f) Return Receipt Postcard &amp; Express</p>		

This collection of information is required by 37 CFR 1.414 AND 1.491-1.492. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>107554712</b>		INTERNATIONAL APPLICATION NO. PCT/EP2004/050621		ATTORNEY'S DOCKET NUMBER TIP0045-USPCT	
21. <input checked="" type="checkbox"/> The following fees are submitted:				Applicant use	Office use only
<input checked="" type="checkbox"/> a) Basic national fee ..... <b>\$300.00</b> <input checked="" type="checkbox"/> b) Examination fee ..... <b>\$200.00</b> <input checked="" type="checkbox"/> c) Search fee ..... <b>\$500.00</b> <b>TOTAL OF ABOVE CALCULATIONS = \$ 1000.00</b>				\$ 300.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)		RATE	
52 - 100 =	0 /50 =	0		x \$250.00	\$
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED		NUMBER EXTRA	RATE	
Total claims	12 -20		0	x \$50.00	
Independent claims	4 - 3		1	x 200.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$300.00	\$
				<b>TOTAL OF ABOVE CALCULATIONS =</b>	<b>\$1200.00</b>
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
				<b>SUBTOTAL =</b>	<b>\$1200.00</b>
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
				<b>TOTAL NATIONAL FEE =</b>	<b>\$</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
				<b>TOTAL FEES ENCLOSED =</b>	<b>\$1200.00</b>
Amount to be refunded:				\$	
Amount to be charged:				\$	
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>10-0750/TIP0045-USPCT/AGK</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>10-0750/TIP0045-USPCT/AGK</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit Card Information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Philip S. Johnson, Esq. Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 USA					
 Signature Name: Alana G. Kriegsman Reg. No. 41,747 Attorney for Applicants					
Dated: October 27, 2005					

10/554712  
JC06 Rec'd PCT/PTO 27 OCT 2005

Express Mail Label No. EV 546119892 US  
Docket No. TIP0045-USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: VERSCHUEREN, Wim Gaston  
DIERYNCK, Inge  
SURLERAUX, Dominique, Louis, Nestor, Ghislain  
DAEYAERT, Frederik, Frans, Desire

For: HIV INTEGRASE INHIBITORS

Express Mail Certificate

"Express Mail" mailing number: EV 546119892 US

Date of Deposit: October 27, 2005


I hereby certify that this entry into the National Phase pursuant to 35 USC 371 contains complete application:

<input checked="" type="checkbox"/>	Express Mail Certificate	(1 page)
<input checked="" type="checkbox"/>	Return Receipt Postcard	(1 page)
<input checked="" type="checkbox"/>	PCT FORM 1390 Transmittal	(2 pages & copy)
<input checked="" type="checkbox"/>	Copy of International Application as filed WO2004/096807 A2 (also attached WO2004/096807 A3/corrected version)	(103 pages)
<input checked="" type="checkbox"/>	Specification	(95 pages)
<input checked="" type="checkbox"/>	Verified Statement Under 37 CFR §1.821(f)	(1 page)
<input checked="" type="checkbox"/>	Gene Sequence Listing – Paper Copy	(1 page)
<input checked="" type="checkbox"/>	Diskette: Gene Sequence Listing in Computer Readable Format (txt. And PatIn 3.3)	(1)
<input checked="" type="checkbox"/>	Copy of PCT Request & Declaration	(13 pages)
<input checked="" type="checkbox"/>	Power of Attorney	(1 page)
<input checked="" type="checkbox"/>	Certificate under 37 CFR 3.73(b)	(8 pages)
<input checked="" type="checkbox"/>	Preliminary Amendment	(21 pages)
<input checked="" type="checkbox"/>	PCT Notification of the Recording Of a Change	(1 page)

is being deposited with the United States Postal Service "Express Mail Post Office to  
Addressee; service under 37 CFR 1.10 on the date indicated above is addressed to the Mail  
Stop: PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450..

Laurie Phillips

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

10/554712

Express Mail Label No. EV 546119892 US  
Docket No. TIP0045-USPCT

JC14 Rec'd PCT/PTO 27 OCT 2005

TIP-045-USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tibotec Pharmaceuticals Ltd.

Serial No.: Art Unit:

Filed : Examiner:

For : HIV INTEGRASE INHIBITORS

Commissioner for Patents  
Washington, D.C. 20231

CERTIFICATE UNDER 37 CFR 3.73(b)

Tibotec Pharmaceuticals Ltd., a Corporation, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application identified above. The assignments were recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B.  A chain of title from the inventor(s), or the patent application identified above, to the current assignee as shown below:

1. From:  
To:  
The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

2. From:  
To:  
The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

3. From:  
To:

The document was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1 August 2005

Date

Frank Daeleman

Signature

Frank Daelemans

Typed or Printed Name

Proxy Holder

Title